Company type | Private (L.P.) |
---|---|
Industry | Pharmaceuticals |
Founded | New York, New York, U.S. 1892 |
Founders | John Purdue Gray George Frederick Bingham |
Fate | Restructuring as Knoa Pharma due to Chapter 11 bankruptcy and legal issues |
Headquarters | , U.S. |
Key people | Craig Landau (President & CEO) Arthur Sackler Mortimer Sackler Raymond Sackler Richard Sackler (President) |
Revenue | Bankruptcy (2023) |
Number of employees | 5,000 (worldwide) |
Subsidiaries | Rhodes Pharma |
Website | www |
Footnotes / references |
Purdue Pharma L.P., formerly the Purdue Frederick Company (1892–2019), was an American privately held pharmaceutical company founded by John Purdue Gray. It was sold to Arthur, Mortimer, and Raymond Sackler in 1952, and then owned principally by the Sackler family and their descendants.[1][2]
The company manufactured pain medicines such as hydromorphone, fentanyl, codeine, hydrocodone and oxycodone, also known by its brand name, OxyContin. The Sacklers developed aggressive marketing tactics persuading doctors to prescribe OxyContin in particular. Doctors were enticed with free trips to pain-management seminars (which were effectively all-expenses-paid vacations) and paid speaking engagements. Sales of their drugs soared, as did the number of people dying from overdoses.[3] From 1999 to 2020, nearly 841,000 people died from drug overdoses in the United States, with prescription and illicit opioids responsible for 500,000 of those deaths.[4]
A series of lawsuits followed. In 2007, Purdue paid out one of the largest fines ever levied against a pharmaceutical firm for misleading the public about how addictive the drug OxyContin was compared to other pain medications.[5][6] In response to the lawsuits, the company shifted its focus to abuse-deterrent formulations, but continued to market and sell opioids as late as 2019 and continued to be involved in lawsuits around the opioid epidemic in the United States.[7][8]
Purdue filed for Chapter 11 bankruptcy protection on September 15, 2019, in New York City.[9][10] On October 21, 2020, it was reported that Purdue had reached a settlement potentially worth US$8.3 billion, admitting that it "knowingly and intentionally conspired and agreed with others to aid and abet" doctors dispensing medication "without a legitimate medical purpose." Members of the Sackler family will additionally pay US$225 million and the company will close.[11][12]
Some state attorneys general protested the plan.[13] In March 2021, the United States House of Representatives introduced a bill that would stop the bankruptcy judge in the case from granting members of the Sackler family legal immunity during the bankruptcy proceedings.[14] The House Judicial Committee referred it to the Subcommittee on Antitrust, Commercial, and Administrative Law in October 2021.[15] The bill lapsed at the end of the 117th Congress in January 2023. In September 2021, Purdue Pharma announced that it would rebrand itself as Knoa Pharma.[16]
As of August, 2023, Purdue Pharma remains in chapter 11 bankruptcy, pending a Department of Justice appeal to the United States Supreme Court, of a 2nd U.S. Circuit Court Of Appeals ruling that the bankruptcy proceedings may continue.[17]
The company's downfall was the subject of the 2021 Hulu miniseries Dopesick, the 2023 Netflix series Painkiller, and several documentaries and books.
Purdue Pharma had no relation to Purdue University or the university's college of pharmacy, something Purdue University has made clear on multiple occasions to avoid association.[18]